Retatrutide is supplied as a triple gip/glp-1/glucagon receptor agonist peptide for qualified laboratory research. It is intended for laboratory studies of GIP, GLP-1 and glucagon receptor signalling, triple-receptor pharmacology, peptide characterisation and metabolic pathway research. Available specifications: 5 mg, 10 mg, 15 mg, 20 mg, 22 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg; 10 vials per box. The featured SKU contains 30 mg in a 3 mL vial, packed 10 vials per box, with a minimum order of 100 boxes (1,000 vials). For laboratory research use only. Not for human consumption, clinical use, diagnosis, treatment, compounding or veterinary use.